An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 Mar 2017 Results (n=67) assessing pharmacokinetics and safety of olaparib using patient data from NCT01894256 and NCT01894243 trials, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 11 May 2016 Time frame for primary endpoints changed.
- 18 Apr 2016 Time frame for primary endpoints changed as well as study design changed from single group assignment to parallel group.